EA201890599A1 - Способ повышения безопасности и эффективности противораковой терапии - Google Patents

Способ повышения безопасности и эффективности противораковой терапии

Info

Publication number
EA201890599A1
EA201890599A1 EA201890599A EA201890599A EA201890599A1 EA 201890599 A1 EA201890599 A1 EA 201890599A1 EA 201890599 A EA201890599 A EA 201890599A EA 201890599 A EA201890599 A EA 201890599A EA 201890599 A1 EA201890599 A1 EA 201890599A1
Authority
EA
Eurasian Patent Office
Prior art keywords
safety
increasing
efficiency
cancer therapy
dnase
Prior art date
Application number
EA201890599A
Other languages
English (en)
Other versions
EA034367B1 (ru
Inventor
Дмитрий Дмитриевич Генкин
Георгий Викторович ТЕЦ
Виктор Вениаминович ТЕЦ
Original Assignee
СиЭлЭс ТЕРАПЬЮТИКС ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СиЭлЭс ТЕРАПЬЮТИКС ЛИМИТЕД filed Critical СиЭлЭс ТЕРАПЬЮТИКС ЛИМИТЕД
Publication of EA201890599A1 publication Critical patent/EA201890599A1/ru
Publication of EA034367B1 publication Critical patent/EA034367B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/22—Endodeoxyribonucleases producing 3'-phosphomonoesters (3.1.22)
    • C12Y301/22001—Deoxyribonuclease II (3.1.22.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Изобретение относится к применению фермента дезоксирибонуклеазы (ДНКазы) с целью предотвращения или облегчения токсичности, связанной с различными цитостатическими и/или цитотоксическими химиотерапевтическими соединениями и лучевой терапией.
EA201890599A 2015-10-29 2015-10-29 Способ повышения безопасности и эффективности противораковой терапии EA034367B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2015/000721 WO2017074211A1 (en) 2015-10-29 2015-10-29 Method to improve safety and efficacy of anti-cancer therapy

Publications (2)

Publication Number Publication Date
EA201890599A1 true EA201890599A1 (ru) 2018-11-30
EA034367B1 EA034367B1 (ru) 2020-01-31

Family

ID=58630741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890599A EA034367B1 (ru) 2015-10-29 2015-10-29 Способ повышения безопасности и эффективности противораковой терапии

Country Status (6)

Country Link
EP (3) EP3878462A1 (ru)
JP (1) JP6761857B2 (ru)
CA (1) CA3001543C (ru)
EA (1) EA034367B1 (ru)
ES (1) ES2876437T3 (ru)
WO (1) WO2017074211A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US20220195491A1 (en) * 2018-06-29 2022-06-23 Viktor Veniaminovich Tets Compositions for modulating gut microbiota

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776838B1 (en) 1987-10-28 2010-08-17 Wellstat Therapeutics Corporation Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5017371A (en) 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
JP2000229881A (ja) * 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
US7462601B2 (en) 2002-03-26 2008-12-09 Tsutomu Kagiya Ameliorant for chemical treatment of cancer
WO2005007187A1 (fr) * 2003-07-14 2005-01-27 Viktor Veniaminovich Tets Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
RU2269359C2 (ru) * 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US7695714B2 (en) 2005-12-28 2010-04-13 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
US7795268B2 (en) 2006-03-17 2010-09-14 Gilead Palo Alto, Inc. Method of treating hepatic disease using A2B adenosine receptor antagonists
WO2008056155A1 (en) 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
WO2008119077A1 (en) 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof

Also Published As

Publication number Publication date
WO2017074211A1 (en) 2017-05-04
EP3368064A1 (en) 2018-09-05
EP3368064B1 (en) 2021-05-19
EA034367B1 (ru) 2020-01-31
CA3001543A1 (en) 2017-05-04
ES2876437T3 (es) 2021-11-12
JP6761857B2 (ja) 2020-09-30
JP2018534281A (ja) 2018-11-22
EP3900786A1 (en) 2021-10-27
EP3878462A1 (en) 2021-09-15
CA3001543C (en) 2023-06-27
EP3368064A4 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
PH12017502298A1 (en) Antibacterial compounds
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
MX2018008128A (es) Conjugado persistente de triple activador que activa el receptor de glucagon, glp-1 y gip.
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
MX2019003938A (es) Compuestos espirociclicos.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
UY36075A (es) Derivados de tubulisina
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
WO2016019270A8 (en) An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017012553A (es) Compuestos espirociclicos.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
GB2553439A (en) Methods for scoring chromosomal instabilities
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2021001612A (es) Compuestos utiles en terapia del vih.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MY167705A (en) Smokeless Incinerator and System Using the Same

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM